Asia Pacific Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, and Others), By Route Of Administration, By Distribution Channel, By Country and Growth Forecast, 2023

List of Tables

The Asia Pacific Guillain-Barre Syndrome Market would witness market growth of 5.1% CAGR during the forecast period (2023-2030).

The China market dominated the Asia Pacific Guillain-Barre Syndrome Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $71,707.6 Thousands by 2030. The Japan market is showcasing a CAGR of 4.4% during (2023 - 2030). Additionally, The India market would register a CAGR of 5.8% during (2023 - 2030).

Therapists collaborate closely with patients to address individual deficits and promote the best possible recovery. Occupational therapy focuses on enhancing activities of daily living (ADLs), fine motor skills, and upper extremity function.

Moreover, adopting treatments and interventions in the Guillain-Barre syndrome market is influenced by several factors, including clinical guidelines, healthcare infrastructure, reimbursement policies, and patient preferences.

As per the data released in 2023 by the India Brand Equity Foundation, it is expected that the Indian pharmaceuticals sector will attain a value of US$65 billion by 2024 and US$130 billion by 2030. Over $25 billion of the projected $50 billion worth of the Indian pharmaceutical business comes from exports. Therefore, the growth of the pharmaceutical industry and the increasing elderly population in the region are driving the market's growth.

Based on Therapeutics, the market is segmented into Intravenous Immunoglobulin, Plasma Exchange, and Others. Based on Route Of Administration, the market is segmented into Parenteral, and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

List of Key Companies Profiled

F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
PTC, Inc.
AstraZeneca PLC
Novartis AG
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
Bayer AG
Merck & Co., Inc.
Bristol Myers Squibb Company

Asia Pacific Guillain-Barre Syndrome Market Report Segmentation

By Therapeutics

Intravenous Immunoglobulin
Plasma Exchange
Others

By Route Of Administration

Parenteral
Oral

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Others

By Country

China
Japan
India
South Korea
Singapore
Malaysia
Rest of Asia Pacific

Chapter 1.Market Scope & Methodology

1.1Market Definition
1.2Objectives
1.3Market Scope
1.4Segmentation
- 1.4.1Asia Pacific Guillain-Barre Syndrome Market, by Therapeutics
- 1.4.2Asia Pacific Guillain-Barre Syndrome Market, by Route Of Administration
- 1.4.3Asia Pacific Guillain-Barre Syndrome Market, by Distribution Channel
- 1.4.4Asia Pacific Guillain-Barre Syndrome Market, by Country
1.5Methodology for the research

Chapter 2.Market at a Glance

2.1Key Highlights

Chapter 3.Market Overview

3.1Introduction
- 3.1.1Overview
  - 3.1.1.1Market Composition and Scenario
3.2Key Factors Impacting the Market
- 3.2.1Market Drivers
- 3.2.2Market Restraints
- 3.2.3Market Opportunities
- 3.2.4Market Challenges
3.3Porter Five Forces Analysis

Chapter 4.Asia Pacific Guillain-Barre Syndrome Market by Therapeutics

4.1Asia Pacific Intravenous Immunoglobulin Market by Country
4.2Asia Pacific Plasma Exchange Market by Country
4.3Asia Pacific Others Market by Country

Chapter 5.Asia Pacific Guillain-Barre Syndrome Market by Route Of Administration

5.1Asia Pacific Parenteral Market by Country
5.2Asia Pacific Oral Market by Country

Chapter 6.Asia Pacific Guillain-Barre Syndrome Market by Distribution Channel

6.1Asia Pacific Hospital Pharmacies Market by Country
6.2Asia Pacific Retail Pharmacies Market by Country
6.3Asia Pacific Others Market by Country

Chapter 7.Asia Pacific Guillain-Barre Syndrome Market by Country

7.1China Guillain-Barre Syndrome Market
- 7.1.1China Guillain-Barre Syndrome Market by Therapeutics
- 7.1.2China Guillain-Barre Syndrome Market by Route Of Administration
- 7.1.3China Guillain-Barre Syndrome Market by Distribution Channel
7.2Japan Guillain-Barre Syndrome Market
- 7.2.1Japan Guillain-Barre Syndrome Market by Therapeutics
- 7.2.2Japan Guillain-Barre Syndrome Market by Route Of Administration
- 7.2.3Japan Guillain-Barre Syndrome Market by Distribution Channel
7.3India Guillain-Barre Syndrome Market
- 7.3.1India Guillain-Barre Syndrome Market by Therapeutics
- 7.3.2India Guillain-Barre Syndrome Market by Route Of Administration
- 7.3.3India Guillain-Barre Syndrome Market by Distribution Channel
7.4South Korea Guillain-Barre Syndrome Market
- 7.4.1South Korea Guillain-Barre Syndrome Market by Therapeutics
- 7.4.2South Korea Guillain-Barre Syndrome Market by Route Of Administration
- 7.4.3South Korea Guillain-Barre Syndrome Market by Distribution Channel
7.5Singapore Guillain-Barre Syndrome Market
- 7.5.1Singapore Guillain-Barre Syndrome Market by Therapeutics
- 7.5.2Singapore Guillain-Barre Syndrome Market by Route Of Administration
- 7.5.3Singapore Guillain-Barre Syndrome Market by Distribution Channel
7.6Malaysia Guillain-Barre Syndrome Market
- 7.6.1Malaysia Guillain-Barre Syndrome Market by Therapeutics
- 7.6.2Malaysia Guillain-Barre Syndrome Market by Route Of Administration
- 7.6.3Malaysia Guillain-Barre Syndrome Market by Distribution Channel
7.7Rest of Asia Pacific Guillain-Barre Syndrome Market
- 7.7.1Rest of Asia Pacific Guillain-Barre Syndrome Market by Therapeutics
- 7.7.2Rest of Asia Pacific Guillain-Barre Syndrome Market by Route Of Administration
- 7.7.3Rest of Asia Pacific Guillain-Barre Syndrome Market by Distribution Channel

Chapter 8.Company Profiles

8.1F. Hoffmann-La Roche Ltd.
- 8.1.1Company Overview
- 8.1.2Financial Analysis
- 8.1.3Segmental and Regional Analysis
- 8.1.4Research & Development Expense
- 8.1.5SWOT Analysis
8.2Pfizer, Inc.
- 8.2.1Company Overview
- 8.2.2Financial Analysis
- 8.2.3Regional & Segmental Analysis
- 8.2.4Research & Development Expense
- 8.2.5SWOT Analysis
8.3PTC, Inc.
- 8.3.1Company Overview
- 8.3.2Financial Analysis
- 8.3.3Segmental and Regional Analysis
- 8.3.4Research & Development Expenses
- 8.3.5SWOT Analysis
8.4AstraZeneca PLC
- 8.4.1Company Overview
- 8.4.2Financial Analysis
- 8.4.3Regional Analysis
- 8.4.4Research & Development Expenses
- 8.4.5SWOT Analysis
8.5Novartis AG
- 8.5.1Company Overview
- 8.5.2Financial Analysis
- 8.5.3Segmental and Regional Analysis
- 8.5.4Research & Development Expense
- 8.5.5Recent strategies and developments:
  - 8.5.5.1Partnerships, Collaborations, and Agreements:
- 8.5.6SWOT Analysis
8.6Novo Nordisk A/S
- 8.6.1Company Overview
- 8.6.2Financial Analysis
- 8.6.3Segmental and Regional Analysis
- 8.6.4Research & Development Expenses
- 8.6.5SWOT Analysis
8.7Takeda Pharmaceutical Company Limited
- 8.7.1Company Overview
- 8.7.2Financial Analysis
- 8.7.3Regional Analysis
- 8.7.4Research & Development Expense
- 8.7.5SWOT Analysis
8.8Bayer AG
- 8.8.1Company Overview
- 8.8.2Financial Analysis
- 8.8.3Segmental and Regional Analysis
- 8.8.4Research & Development Expense
- 8.8.5SWOT Analysis
8.9Merck & Co., Inc.
- 8.9.1Company Overview
- 8.9.2Financial Analysis
- 8.9.3Segmental and Regional Analysis
- 8.9.4Research & Development Expenses
- 8.9.5Recent strategies and developments:
  - 8.9.5.1Partnerships, Collaborations, and Agreements:
- 8.9.6SWOT Analysis
8.10.Bristol Myers Squibb Company
- 8.10.1Company Overview
- 8.10.2Financial Analysis
- 8.10.3Regional Analysis
- 8.10.4Research & Development Expenses
- 8.10.5SWOT Analysis

LIST OF TABLES

TABLE 1Asia Pacific Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 2Asia Pacific Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 3Asia Pacific Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 4Asia Pacific Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 5Asia Pacific Intravenous Immunoglobulin Market by Country, 2019 - 2022, USD Thousands
TABLE 6Asia Pacific Intravenous Immunoglobulin Market by Country, 2023 - 2030, USD Thousands
TABLE 7Asia Pacific Plasma Exchange Market by Country, 2019 - 2022, USD Thousands
TABLE 8Asia Pacific Plasma Exchange Market by Country, 2023 - 2030, USD Thousands
TABLE 9Asia Pacific Others Market by Country, 2019 - 2022, USD Thousands
TABLE 10Asia Pacific Others Market by Country, 2023 - 2030, USD Thousands
TABLE 11Asia Pacific Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 12Asia Pacific Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 13Asia Pacific Parenteral Market by Country, 2019 - 2022, USD Thousands
TABLE 14Asia Pacific Parenteral Market by Country, 2023 - 2030, USD Thousands
TABLE 15Asia Pacific Oral Market by Country, 2019 - 2022, USD Thousands
TABLE 16Asia Pacific Oral Market by Country, 2023 - 2030, USD Thousands
TABLE 17Asia Pacific Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 18Asia Pacific Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 19Asia Pacific Hospital Pharmacies Market by Country, 2019 - 2022, USD Thousands
TABLE 20Asia Pacific Hospital Pharmacies Market by Country, 2023 - 2030, USD Thousands
TABLE 21Asia Pacific Retail Pharmacies Market by Country, 2019 - 2022, USD Thousands
TABLE 22Asia Pacific Retail Pharmacies Market by Country, 2023 - 2030, USD Thousands
TABLE 23Asia Pacific Others Market by Country, 2019 - 2022, USD Thousands
TABLE 24Asia Pacific Others Market by Country, 2023 - 2030, USD Thousands
TABLE 25Asia Pacific Guillain-Barre Syndrome Market by Country, 2019 - 2022, USD Thousands
TABLE 26Asia Pacific Guillain-Barre Syndrome Market by Country, 2023 - 2030, USD Thousands
TABLE 27China Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 28China Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 29China Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 30China Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 31China Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 32China Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 33China Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 34China Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 35Japan Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 36Japan Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 37Japan Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 38Japan Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 39Japan Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 40Japan Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 41Japan Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 42Japan Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 43India Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 44India Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 45India Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 46India Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 47India Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 48India Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 49India Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 50India Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 51South Korea Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 52South Korea Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 53South Korea Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 54South Korea Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 55South Korea Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 56South Korea Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 57South Korea Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 58South Korea Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 59Singapore Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 60Singapore Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 61Singapore Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 62Singapore Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 63Singapore Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 64Singapore Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 65Singapore Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 66Singapore Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 67Malaysia Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 68Malaysia Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 69Malaysia Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 70Malaysia Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 71Malaysia Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 72Malaysia Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 73Malaysia Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 74Malaysia Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 75Rest of Asia Pacific Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 76Rest of Asia Pacific Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 77Rest of Asia Pacific Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 78Rest of Asia Pacific Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 79Rest of Asia Pacific Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 80Rest of Asia Pacific Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 81Rest of Asia Pacific Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 82Rest of Asia Pacific Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 83Key Information - F. Hoffmann-La Roche Ltd.
TABLE 84Key Information - Pfizer, Inc.
TABLE 85key Information - PTC, Inc.
TABLE 86KEY INFORMATION - AstraZeneca PLC
TABLE 87Key Information - Novartis AG
TABLE 88Key Information - Novo Nordisk A/S
TABLE 89Key Information - Takeda Pharmaceutical Company Limited
TABLE 90Key Information - Bayer AG
TABLE 91Key Information - Merck & Co., Inc.
TABLE 92Key Information - Bristol Myers Squibb Company

Asia Pacific Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, and Others), By Route Of Administration, By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

Description

Table of Contents